Pelthos Therapeutics is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.
ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum is now approved by the U.S. Food and Drug Administration. Complete prescribing information and important safety information is available at www.zelsuvmi.com. Additionally, Pelthos acquired Xepi® (ozenoxacin) Cream, 1% a topical treatment for impetigo and Xeglyze® (abametapir) topical treatment for head lice in the 4th Quarter of 2025 with targeted commercial availability in the second half of 2026 and the first half of 2027 respectively.